Search

Your search keyword '"Hyrich, K."' showing total 297 results
Start Over Author "Hyrich, K."
297 results on '"Hyrich, K."'

1. OP0092 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: FINDINGS FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY)

Author

Aymon, R., primary, Mongin, D., additional, Gilbert, B., additional, Guemara, R., additional, Choquette, D., additional, Codreanu, C., additional, Flouri, I., additional, Huschek, D., additional, Hyrich, K., additional, Iannone, F., additional, Kearsley-Fleet, L., additional, Kvien, T. K., additional, Leeb, B. F., additional, Nordström, D., additional, Pavelka, K., additional, Pombo-Suarez, M., additional, Aarrestad Provan, S., additional, Rodrigues, A. M., additional, Rotar, Z., additional, Sidiropoulos, P., additional, Strangfeld, A., additional, Trokovic, N., additional, Zavada, J., additional, Courvoisier, D. S., additional, Finckh, A., additional, and Lauper, K., additional

Published
2024
Full Text
View/download PDF

5. Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry

Author

Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, Machado, PM, Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, and Machado, PM

Abstract

Objective: Approximately one third of individuals worldwide have not received a COVID-19 vaccine. Although studies have investigated risk factors linked to severe COVID-19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID-19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern. Methods: Patients with RDs and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID-19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID-19 pandemic epochs; subanalyses stratified patients according to RD types. Results: Among 19,256 unvaccinated people with RDs and COVID-19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B-cell–depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B-cell–depleting therapy was associated with worse outcomes. Conclusion: Risk factors for severe COVID-19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID-19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.

Published
2024

8. AB0411 ASSOCIATION BETWEEN ETHNICITY AND INITIAL RESPONSE TO TNF INHIBITORS IN PEOPLE WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA)

Author

Tsoi, M. F., primary, Andev, R. S., additional, Kearsley-Fleet, L., additional, Watson, K., additional, Dubey, S., additional, Kumar, K., additional, Moorthy, A., additional, Gupta, M., additional, Adebajo, A., additional, and Hyrich, K., additional

Published
2023
Full Text
View/download PDF

14. OP0219 INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO BDMARDS: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTRIES (THE “JAK-POT” STUDY)

Author

Aymon, R., primary, Mongin, D., additional, Bergstra, S. A., additional, Choquette, D., additional, Codreanu, C., additional, Cordtz, R. L., additional, Diederik, D. C., additional, Dreyer, L., additional, Elkayam, O., additional, Huschek, D., additional, Hyrich, K., additional, Iannone, F., additional, Inanc, N., additional, Kearsley-Fleet, L., additional, Kvien, T. K., additional, Leeb, B., additional, Lukina, G., additional, Nordström, D., additional, Onen, F., additional, Pavelka, K., additional, Pombo-Suarez, M., additional, Aarrestad Provan, S., additional, Rodrigues, A. M., additional, Rotar, Z., additional, Strangfeld, A., additional, Verschueren, P., additional, Zavada, J., additional, Courvoisier, D., additional, Finckh, A., additional, and Lauper, K., additional

Published
2023
Full Text
View/download PDF

18. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., MacHado P. M., Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., and MacHado P. M.

Abstract

Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death. Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65-1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51-0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively). Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These

Published
2022

19. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

Author

Jatuworapruk, K, Montgomery, A, Gianfrancesco, M, Conway, R, Durcan, L, Graef, E, Jayatilleke, A, Keen, H, Kilian, A, Young, K, Carmona, L, Cogo, A, Duarte-Garcia, A, Gossec, L, Hasseli, R, Hyrich, K, Langlois, V, Lawson-Tovey, S, Malcata, A, Mateus, E, Schafer, M, Scire, C, Sigurdardottir, V, Sparks, J, Strangfeld, A, Xavier, R, Bhana, S, Gore-Massy, M, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Wallace, Z, Machado, P, Yazdany, J, Grainger, R, Robinson, P, Jatuworapruk K., Montgomery A., Gianfrancesco M., Conway R., Durcan L., Graef E. R., Jayatilleke A., Keen H., Kilian A., Young K., Carmona L., Cogo A. K., Duarte-Garcia A., Gossec L., Hasseli R., Hyrich K. L., Langlois V., Lawson-Tovey S., Malcata A., Mateus E. F., Schafer M., Scire C. A., Sigurdardottir V., Sparks J. A., Strangfeld A., Xavier R. M., Bhana S., Gore-Massy M., Hausmann J., Liew J. W., Sirotich E., Sufka P., Wallace Z., Machado P. M., Yazdany J., Grainger R., Robinson P. C., Jatuworapruk, K, Montgomery, A, Gianfrancesco, M, Conway, R, Durcan, L, Graef, E, Jayatilleke, A, Keen, H, Kilian, A, Young, K, Carmona, L, Cogo, A, Duarte-Garcia, A, Gossec, L, Hasseli, R, Hyrich, K, Langlois, V, Lawson-Tovey, S, Malcata, A, Mateus, E, Schafer, M, Scire, C, Sigurdardottir, V, Sparks, J, Strangfeld, A, Xavier, R, Bhana, S, Gore-Massy, M, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Wallace, Z, Machado, P, Yazdany, J, Grainger, R, Robinson, P, Jatuworapruk K., Montgomery A., Gianfrancesco M., Conway R., Durcan L., Graef E. R., Jayatilleke A., Keen H., Kilian A., Young K., Carmona L., Cogo A. K., Duarte-Garcia A., Gossec L., Hasseli R., Hyrich K. L., Langlois V., Lawson-Tovey S., Malcata A., Mateus E. F., Schafer M., Scire C. A., Sigurdardottir V., Sparks J. A., Strangfeld A., Xavier R. M., Bhana S., Gore-Massy M., Hausmann J., Liew J. W., Sirotich E., Sufka P., Wallace Z., Machado P. M., Yazdany J., Grainger R., and Robinson P. C.

Abstract

Objective To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes. Methods Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death. Results One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. Conclusion This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.

Published
2022

21. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, Strangfeld A., Schafer M., Gianfrancesco M. A., Lawson-Tovey S., Liew J. W., Ljung L., Mateus E. F., Richez C., Santos M. J., Schmajuk G., Scire C. A., Sirotich E., Sparks J. A., Sufka P., Thomas T., Trupin L., Wallace Z. S., Al-Adely S., Bachiller-Corral J., Bhana S., Cacoub P., Carmona L., Costello R., Costello W., Gossec L., Grainger R., Hachulla E., Hasseli R., Hausmann J. S., Hyrich K. L., Izadi Z., Jacobsohn L., Katz P., Kearsley-Fleet L., Robinson P. C., Yazdany J., Machado P. M., Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, Strangfeld A., Schafer M., Gianfrancesco M. A., Lawson-Tovey S., Liew J. W., Ljung L., Mateus E. F., Richez C., Santos M. J., Schmajuk G., Scire C. A., Sirotich E., Sparks J. A., Sufka P., Thomas T., Trupin L., Wallace Z. S., Al-Adely S., Bachiller-Corral J., Bhana S., Cacoub P., Carmona L., Costello R., Costello W., Gossec L., Grainger R., Hachulla E., Hasseli R., Hausmann J. S., Hyrich K. L., Izadi Z., Jacobsohn L., Katz P., Kearsley-Fleet L., Robinson P. C., Yazdany J., and Machado P. M.

Abstract

Objectives To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category. Results Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death. Conclusion Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dos

Published
2021

22. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., Yazdany J., Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., and Yazdany J.

Abstract

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. Results Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. Conclusions People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

23. OP0266 TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS AS AN OVERALL MEASURE OF TOLERANCE AND SAFETY OF JAK-INHIBITORS: AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-pot” STUDY).

Author

Nham, E., primary, Aymon, R., additional, Mongin, D., additional, Bergstra, S. A., additional, Choquette, D., additional, Codreanu, C., additional, Elkayam, O., additional, Hyrich, K., additional, Iannone, F., additional, Inanc, N., additional, Kearsley-Fleet, L., additional, Kristianslund, E., additional, Kvien, T. K., additional, Leeb, B., additional, Lukina, G., additional, Nordström, D., additional, Pavelka, K., additional, Pombo-Suarez, M., additional, Rotar, Z., additional, Santos, M. J., additional, Courvoisier, D., additional, Lauper, K., additional, and Finckh, A., additional

Published
2022
Full Text
View/download PDF

29. OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES

Author

Machado, P. M., primary, Schaefer, M., additional, Mahil, S., additional, Dand, N., additional, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Yiu, Z., additional, Yates, M., additional, Hyrich, K., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Wiek, D., additional, Bhana, S., additional, Gore-Massy, M., additional, Grainger, R., additional, Hausmann, J., additional, Sufka, P., additional, Sirotich, E., additional, Wallace, Z., additional, Olofsson, T., additional, Lomater, C., additional, Romeo, N., additional, Wendling, D., additional, Pham, T., additional, Miceli Richard, C., additional, Fautrel, B., additional, Silva, L., additional, Santos, H., additional, Martins, F. R., additional, Hasseli, R., additional, Pfeil, A., additional, Regierer, A., additional, Isnardi, C., additional, Soriano, E., additional, Quintana, R., additional, Omura, F., additional, Machado Ribeiro, F., additional, Pinheiro, M., additional, Bautista-Molano, W., additional, Alpizar-Rodriguez, D., additional, Saad, C., additional, Dubreuil, M., additional, Haroon, N., additional, Gensler, L. S., additional, Dau, J., additional, Jacobsohn, L., additional, Liew, J., additional, Strangfeld, A., additional, Barker, J., additional, Griffiths, C. E. M., additional, Robinson, P., additional, Yazdany, J., additional, and Smith, C., additional

Published
2022
Full Text
View/download PDF

32. OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY

Author

Yeoh, S. A., primary, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Schaefer, M., additional, Richez, C., additional, Hachulla, E., additional, Holmqvist, M., additional, Scirè, C. A., additional, Hasseli, R., additional, Jayatilleke, A., additional, Hsu, T., additional, D’Silva, K., additional, Pimentel-Quiroz, V., additional, Vasquez del Mercado, M., additional, Katsuyuki Shinjo, S., additional, Reis Neto, E., additional, Rocha, L., additional, Montandon, A. C. D. O. E. S., additional, Jordan, P., additional, Sirotich, E., additional, Hausmann, J., additional, Liew, J., additional, Jacobsohn, L., additional, Gore-Massy, M., additional, Sufka, P., additional, Grainger, R., additional, Bhana, S., additional, Wallace, Z., additional, Robinson, P., additional, Yazdany, J., additional, and Machado, P., additional

Published
2022
Full Text
View/download PDF

38. POS1212 SARS-CoV-2 VACCINE SAFETY IN ADOLESCENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES AND ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS

Author

Lawson-Tovey, S., primary, Strangfeld, A., additional, Mateus, E., additional, Gossec, L., additional, Carmona, L., additional, Machado, P., additional, Raffeiner, B., additional, Bulina, I., additional, Clemente, D., additional, Zepa, J., additional, Rodrigues, A. M., additional, Mariette, X., additional, and Hyrich, K., additional

Published
2022
Full Text
View/download PDF

39. Risk of severe COVID-19 associated with immune-modifying drugs: Data from PsoProtect and Global Rheumatology Alliance registries.

Author

Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, Smith CH., Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, and Smith CH.

Published
2022

40. Tolérance de la vaccination contre le SRAS-CoV-2 chez les patients atteints de maladies rhumatologiques inflammatoires/auto-immunes : résultats du registre EULAR-COVAX chez 5121 patients

Author

Mariette, X., primary, Lawson-Tovey, S., additional, Hachulla, E., additional, Veillard, E., additional, Trefond, L., additional, Soubrier, M., additional, Roux, N., additional, Brocq, O., additional, Durez, P., additional, Goulenok, T., additional, Gossec, L., additional, Strakova, E., additional, Burmester, G.R., additional, Kübra, Y.G., additional, Gomez, P.J.A., additional, Zepa, J., additional, Hyrich, K., additional, Cunha, M.M., additional, Mosca, M., additional, Cornalba, M., additional, Mateus, E., additional, Carmona, L., additional, Rodrigues, A., additional, Raffeiner, B., additional, Conway, R., additional, Strangfeld, A., additional, Bijlsma, H., additional, McInnes, I.B., additional, and Machado, P., additional

Published
2021
Full Text
View/download PDF

41. HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY)

Author

Lauper, K., Mongin, D., Bergstra, S. A., Choquette, D., Codreanu, C., De Cock, D., Dreyer, L., Elkayam, O., Hyrich, K., Iannone, F., Inanc, N., Kristianslund, E., Kvien, T. K., Leeb, B., Lukina, G., Nordstrom, D., Pavelka, K., Pombo-Suarez, M., Rotar, Z., Santos, M. J., Strangfeld, A., Courvoisier, D., and Finckh, A.

Published
2021
Full Text
View/download PDF

42. Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach

Author

Yarwood, Annie, Viatte, Sebastien, Plant, Darren, Morgan, Ann W, Isaacs, John, Wilson, Anthony G, Hyrich, Kimme, Eyre, Steve, Barton, Anne, Gaston, H, Mulherin, D, Price, T, Sheeran, T, Chalam, V, Baskar, S, Emery, P, Morgan, A W, Buch, M, Bingham, S, O’Reilly, S, Badcock, L, Regan, M, Ding, T, Deighton, C, Summers, G, Raj, N, Stevens, R, Williams, N, Isaacs, J, Platt, P, Walker, D, Kay, L, Griffiths, B, Ng, W-F, Peterson, P, Lorenzi, A, Foster, H, Friswell, M, Thompson, B, Lee, M, Griffiths, I, Hassell, A, Dawes, P, Dowson, C, Kamath, S, Packham, J, Shadforth, M, Williams, R, Mukhtyar, C, Harrison, B, Snowden, N, Naz, S, Ledingham, J, Hull, R, McCrae, F, Thomas, A, Young Min, S, Shaban, R, Wong, E, Kelly, C, Heycock, C, Hamilton, J, Saravanan, V, Wilson, G, Bax, D, Dunkley, L, Akil, M, Tattersall, R, Kilding, R, Till, S, Boulton, J, Tait, T, Bukhari, M, Halsey, J, Ottewell, L, Buckley, C, Situnayake, D, Carruthers, D, Grindulis, K, Khatack, F, Elamanchi, S, Raza, K, Filer, A, Jubb, R, Abernathy, R, Plant, M, Pathare, S, Clarke, F, Tuck, S, Fordham, J, Paul, A, Bridges, M, Hakim, A, O’Reilly, D, Rajagopal, V, Bhagat, S, Edwards, C, Prouse, P, Moitra, R, Shawe, D, Bamji, A, Klimiuk, P, Bowden, A, Mitchell, W, Bruce, I, Barton, A, Gorodkin, R, Ho, P, Hyrich, K, Dixon, W, Rai, A, Kitas, G, Erb, N, Klocke, R, Douglas, K, Pace, A, Sandhu, R, Whallett, A, Birrell, F, Allen, M, Chaudhuri, K, Chattopadhyay, C, McHale, J, Jones, A, Gupta, A, Pande, I, Gaywood, I, Lanyon, P, Courtney, P, Doherty, M, Chinoy, H, O’Neill, T, Herrick, A, Jones, A, Cooper, R, Bucknall, R, Marguerie, C, Rigby, S, Dunn, N, Green, S, Al-Ansari, A, Webber, S, Hopkinson, N, Dunne, C, Quilty, B, Szebenyi, B, Green, M, Quinn, M, Isdale, A, Brown, A, Saleem, B, Samanta, A, Sheldon, P, Hassan, W, Francis, J, Kinder, A, Neame, R, Moorthy, A, Al-Allaf, W, Taggart, A, Fairburn, K, McKenna, F, Green, M, Gough, A, Lawson, C, Piper, M, Korendowych, E, Jenkinson, T, Sengupta, R, Bhalla, A, McHugh, N, Bond, Debbie, Luqmani, R, Bowness, B, Wordsworth, P, David, J, Smith, W, Mewar, D, Tunn, E, Nelson, K, Kennedy, T, Nixon, J, Woolf, A, Davis, M, Hutchinson, D, Endean, A, Coady, D, Wright, D, Morley, C, Raftery, G, Bracewell, C, Kidd, L, Abbas, I, Filer, C, and Kallarackal, G

Published
2014
Full Text
View/download PDF

44. POS0093 HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY)

Author

Lauper, K., primary, Mongin, D., additional, Bergstra, S. A., additional, Choquette, D., additional, Codreanu, C., additional, De Cock, D., additional, Dreyer, L., additional, Elkayam, O., additional, Hyrich, K., additional, Iannone, F., additional, Inanc, N., additional, Kristianslund, E., additional, Kvien, T. K., additional, Leeb, B., additional, Lukina, G., additional, Nordström, D., additional, Pavelka, K., additional, Pombo-Suarez, M., additional, Rotar, Z., additional, Santos, M. J., additional, Strangfeld, A., additional, Courvoisier, D., additional, and Finckh, A., additional

Published
2021
Full Text
View/download PDF

45. OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)

Author

Ugarte-Gil, M. F., primary, Alarcon, G. S., additional, Seet, A., additional, Izadi, Z., additional, Reategui Sokolova, C., additional, Clarke, A. E., additional, Wise, L., additional, Pons-Estel, G., additional, Santos, M. J., additional, Bernatsky, S., additional, Mathias, L., additional, Lim, N., additional, Sparks, J., additional, Wallace, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, Gianfrancesco, M., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

48. OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY

Author

Izadi, Z., primary, Gianfrancesco, M., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Jacobsohn, L., additional, Katz, P., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Valenzuela-Almada, M., additional, Duarte-Garcia, A., additional, Sparks, J., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Wallace, Z., additional, Machado, P., additional, Robinson, P., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

49. OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE

Author

Sparks, J., primary, Wallace, Z., additional, Seet, A., additional, Gianfrancesco, M., additional, Izadi, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Ugarte-Gil, M. F., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

50. POS1183 OUTCOMES OF COVID-19 INFECTION AMONG CHILDREN AND YOUNG PEOPLE WITH PRE-EXISTING RHEUMATIC AND MUSCULOSKELETAL DISEASES

Author

Kearsley-Fleet, L., primary, Lawson-Tovey, S., additional, Costello, R. E., additional, Belot, A., additional, Aeschlimann, F., additional, Melki, I., additional, Koné-Paut, I., additional, Clemente, D., additional, Pinedo Gago, M. C., additional, Svestkova, N., additional, Vinšová, N., additional, Hamad Saied, M., additional, Berkun, Y., additional, Wulffraat, N., additional, Eulert, S., additional, Scirè, C. A., additional, Strangfeld, A., additional, Mateus, E., additional, Machado, P., additional, Uziel, Y., additional, and Hyrich, K., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results